24 Oct Exact Sciences Expands Leadership In Colorectal Cancer Screening With New Data Presented At The American College Of Gastroenterology 2022 Annual Meeting
Data presentations include positive impact of eliminating patient cost for follow-up colonoscopies, shifting to non-invasive colorectal cancer testing, and increasing overall screening as 900 deaths averted per 1 million people screened.
MADISON, Wis., Oct. 24, 2022 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present new data supporting the positive impact of Cologuard® as a colorectal cancer screening tool during the American College of Gastroenterology (ACG) Annual Meeting, being held October 21-26, 2022. For the first time, data from Exact Sciences will detail the positive impacts on patients when costs associated with follow-up colonoscopy are eliminated after a positive stool-based test. New data will also provide details on the value of Cologuard® in detecting serrated polyps, and the importance of reconsidering the definition of false positive outcomes from stool tests in CRC screening.
“Data from Exact Sciences at ACG demonstrate the positive impact removing obstacles to colorectal cancer screening can have on clinical and economic outcomes associated with this highly preventable form of cancer,” said Paul Limburg, MD MPH, AGAF, chief medical officer, Screening, Exact Sciences. “These results provide key information to help screen more people for colorectal cancer and support the use of Cologuard as an FDA-approved, non-invasive screening option that is included in U.S. Preventive Services Task Force guidelines.”